About Us Science & Technology Portfolio Join Us Investors & News

Investors & News

Investors

Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP’s strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.

News

05.19.2023

Scientific Poster — Non-viral delivery of ABCA4 to photoreceptors (American Society of Gene and Cell Therapy 26th Annual Meeting)

05.17.2023

Scientific Poster — COMET-mediated delivery of C³DNA in human cell-based in vitro models of retinal pigment epithelium (American Society of Gene and Cell Therapy 26th Annual Meeting)

05.16.2023

Intergalactic Therapeutics to Host Virtual KOL Investor Event on May 23, 2023

05.11.2023

Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting

04.29.2023

Ophthalmology Times — ARVO LIVE: Non-viral gene therapy targeting ABCA4 retinopathies

04.20.2023

Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit

04.05.2023

PharmaVoice – Woman of the Week: Intergalactic Therapeutics’ Dr. Theresa Heah

03.17.2023

CGTLive – ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Studies

03.16.2023

BioPharma-Reporter – Intergalactic plans to progress non-viral gene therapy program into the clinic

03.15.2023

Ophthalmology Times – Intergalactic Therapeutics announces positive preclinical results of its platform in ABCA4 retinopathies

03.15.2023

Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies

03.08.2023

Labiotech.eu – 5 female-led biotech startups making waves

01.06.2023

Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer

01.04.2023

BioSpace – Top Life Sciences Startups to Watch in 2023

01.20.2022

Intergalactic Therapeutics Announces Scientific Advisory Board Membership

10.07.2021

ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding